FDA Emphasizes Clinical Trial Flexibility During Coronavirus Pandemic
FDA guidance updated in mid-April offered workarounds for trial sponsors attempting to conduct clinical studies in a time of travel limitations, staffing changes and heightened patient safety issues. For trials involving complex products and administration, such as cell and gene therapies, sponsors must determine whether modified protocols can still maintain trial integrity. If not, it may be time to press pause.
You may also be interested in...
For most patients, drug distributors – companies that provide, control and manage drug supplies – operate as an unseen but critical link in the supply chain. In the context of a global pandemic, however, drug distributors play an even bigger role in helping to ensure that pharmacies, health systems and ultimately patients have access to essential medicines.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment.